Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
about
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infantsRetinopathy of prematurity: Past, present and futureCardiovascular drugs in the treatment of infantile hemangiomaCompound 49b Restores Retinal Thickness and Reduces Degenerate Capillaries in the Rat Retina following Ischemia/ReperfusionStudy protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism.Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic optionsOcular Safety of Intravitreal Propranolol and Its Efficacy in Attenuation of Choroidal Neovascularization.Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathyThe Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index.β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathyInfantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis.Revisiting the mouse model of oxygen-induced retinopathy.The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge.Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation.On the use of antiangiogenetic medications for retinopathy of prematurityBiphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier.Retinopathy of prematurity: Risk factors and variability in Canadian neonatal intensive care units.Expression of β-adrenergic receptors in pediatric malignant brain tumors.Propranolol concentrations after oral administration in term and preterm neonates.Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants.The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance between Apoptosis and Autophagy.Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization.Topical Timolol Inhibits Corneal Neovascularization in Rabbits.IGF-1R Regulates the Extracellular Level of Active MMP-2, Pathological Neovascularization, and Functionality in Retinas of OIR Mouse Model.Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial.EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.The progress of prophylactic treatment in retinopathy of prematurity.Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trialOral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study
P2860
Q24187442-623B5731-F46A-4680-A90C-DB86451F1E50Q26767012-352D1B75-FADE-4C62-B171-DA559A5DC977Q26769978-9844DD6F-1C11-4427-A577-12CBD6F0AA70Q28552739-2171136E-35E0-4702-9BF2-0A0A38439B82Q30992212-9F28BA5B-1E49-413F-A958-21D919DF1B21Q34543206-F65D9D02-B560-4A9B-BCD5-D949618ED70FQ34704214-53CD0998-E351-4BCA-A7D4-A945260F5C96Q35882658-70747D4B-3BF9-409A-B7CE-B19E4656BC88Q36035023-F9837613-50AF-4956-86B8-701492E35A58Q36040633-E2D95D1E-E8B7-4E47-94F0-BC44C3F3F012Q36257726-61BCBECD-5C01-4D23-837A-70A938EB98A4Q36379513-BF73C980-7AB9-410E-8A96-62574387E633Q36875692-6857E5C2-16E7-4510-93F6-D5A31F826686Q37155762-84295C66-88B6-45E5-A108-9026C5F07A4FQ38101684-A8042680-51B5-4B03-A74B-1451667AC1F4Q38293740-B5218639-4616-4097-8E76-2CD017D18532Q38373964-7B1ED2D0-3F07-426A-9720-944861C9CAC4Q38781876-FAD58956-84F6-4C31-9C1D-89D177985FABQ38906895-460CA004-35D9-48A7-AE3D-78527F882FB6Q39238169-650B1145-D908-49D0-8E88-20A53F6B7858Q39239140-33921435-496F-4445-B99E-3B09FC94DD6FQ40409839-E8609977-E5BE-4D33-96CB-0F69FC32B557Q41902409-39F9C71C-F796-4A1D-9B92-44A2FFA80DEDQ44663019-85306357-CB98-49FF-8E1D-6A62B2E128DFQ45418272-2A2E8001-7973-4646-8980-5923B1035B21Q47708800-952E2761-8ED7-4C9B-88AB-B16859B08466Q47880195-560CC28A-6B36-4EB0-8913-9E97DC27A01AQ49211752-8D572204-B230-49BA-9493-5E0604BEB668Q50948454-5C72BB81-35F0-442C-9EEF-2C31EB1E2CEFQ51425178-43EF46D5-D098-406F-883A-4326EB699AB7Q51742975-84591766-1927-4319-9073-CAC8EC5798E9Q54999086-57C365EA-D08E-4930-8866-3577A9229A93Q56527442-51A9386C-9C0F-4ABD-979B-D5CC64DFB8BCQ56989404-64485220-ADC7-4A80-B71A-4B17177868C2
P2860
Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@en
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@nl
type
label
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@en
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@nl
prefLabel
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@en
Role of the adrenergic system ...... beta-adrenoreceptor blockade.
@nl
P2093
P356
P1476
Role of the adrenergic system ...... f beta-adrenoreceptor blockade
@en
P2093
Chiara Ristori
Davide Martini
Massimo Dal Monte
Maurizio Cammalleri
Paola Bagnoli
Patrizio Fiorini
Pina Fortunato
P304
P356
10.1167/IOVS.10-5536
P407
P577
2011-01-05T00:00:00Z